The only therapy available for a disease with a clear unmet medical need will not be made available to UK patients Novartis today expressed disappointment at the National Institute for Health and Clinical Excellence's decision to publish final guidance not recommending ruxolitinib for the treatment of disease-related splenomegaly or symptoms in ... (more)
http://www.medicalnewstoday.com/releases/262512.php
http://www.medicalnewstoday.com/releases/262512.php
No comments:
Post a Comment